When medications and conservative treatments fail, nasal polyp surgery becomes a vital option for relief. This minimally ...

A decision to proceed with nasal polyp surgery was recorded in just 0.5% of tezepelumab-treated patients compared to 22.1% in the placebo group (hazard ratio, 0.02). Systemic glucocorticoid use ...

Medications can shrink nasal polyps. Surgery is often needed to remove them, but they can grow back unless the underlying cause is addressed.

Results from a drug trial showed AstraZeneca and Amgen's new drug Tezspire significantly reduced nasal polyp severity, the need for surgery and anti-inflammatory steroid use in patients with ...

The need for systemic corticosteroids fell by 88%, and the need for surgery fell by 98%. Nasal polyp and congestion scores fell, along with loss of smell and total symptom scores. SAN DIEGO ...

Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery ...

The drug improved both the size of nasal polyps at week 52 and in nasal obstruction during weeks 49-52, compared to placebo when added to standard of care, and extended the time to surgery by 57%.